HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study).
Cannabis
Chronic
Hepatitis C
Human immunodeficiency virus
Smoking cessation
Tobacco
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
19
04
2021
pubmed:
28
4
2021
medline:
23
11
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
In Western countries, tobacco smoking is highly prevalent among patients co-infected with HIV and hepatitis C virus (HCV). In the era of antiretrovirals and HCV cure, smoking-related health damages contribute greatly to morbidity and mortality in HIV-HCV co-infected patients. We used longitudinal data from the ANRS CO13 HEPAVIH cohort to identify the correlates of tobacco smoking quit attempts (TSQA) in HIV-HCV co-infected patients. TSQA were modelled using a multivariable discrete-time Cox proportional hazards model in 695 HIV-HCV co-infected tobacco smokers. HCV cure was associated with a 76% higher chance of TSQA (adjusted hazard ratio [95% confidence interval]: 1.76 [1.06-2.93], p = 0.029), and cannabis use with a 37% lower chance (0.63 [0.40-1.00], p = 0.049), independently of the mode of HIV transmission, other psychoactive substance use, and body mass index. Patients should be screened for tobacco and cannabis use at HCV treatment initiation and during follow-up. They should also be provided with comprehensive counselling and referral to addiction services. Non-smoking routes of cannabis administration should be promoted for cannabis users who wish to quit smoking tobacco.
Identifiants
pubmed: 33903998
doi: 10.1007/s10461-021-03277-x
pii: 10.1007/s10461-021-03277-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4141-4153Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Park LS, Hernández-Ramírez RU, Silverberg MJ, Crothers K, Dubrow R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS Lond Engl. 2016;30(2):273–91.
Tron L, Lert F, Spire B, Dray-Spira R. Tobacco smoking in HIV-infected versus general population in france: heterogeneity across the various groups of people living with HIV. PLoS ONE. 2014;9(9):e107451.
pubmed: 25202968
pmcid: 4159331
Conseil national du SIDA et des hépatites virales (CNS), Agence nationale de recherche sur le sida et les hépatites virales (ANRS). Epidémiologie de l’infection à VIH en France (juillet 2017) [Epidemiology of HIV infection in France]. CNS/ANRS. https://cns.sante.fr/wp-content/uploads/2017/10/experts-vih_epidemio.pdf (2017). Accessed 10 June 2020
Andler R, Richard J-B, Guignard R, Quatremère G, Verrier F, Gane J, et al. Reduction of daily smoking rate among adults: results from the 2018 Santé Publique France health barometer. Bull Epidémiol Hebd. 2019;15:271–7.
Reynolds NR. Cigarette smoking and hiv: more evidence for action. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 2009;21(3 Suppl):106–21.
Marshall MM, Kirk GD, Caporaso NE, McCormack MC, Merlo CA, Hague JC, et al. Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users. Addict Behav. 2010;36(1–2):61–7.
pubmed: 20875704
pmcid: 2981673
McKirnan DJ, Tolou-Shams M, Turner L, Dyslin K, Hope B. Elevated risk for tobacco use among men who have sex with men is mediated by demographic and psychosocial variables. Subst Use Misuse. 2006;41(8):1197–208.
pubmed: 16798685
Barré T, Nishimwe ML, Protopopescu C, Marcellin F, Carrat F, Dorival C, et al. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort). J Viral Hepat. 2020;27(12):1473–83.
pubmed: 32810343
Kim RS, Weinberger AH, Chander G, Sulkowski MS, Norton B, Shuter J. Cigarette smoking in persons living with hepatitis C: the National Health and Nutrition Examination Survey (NHANES), 1999–2014. Am J Med. 2018;131(6):669–75.
pubmed: 29408018
pmcid: 5963992
Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng C-H, Currier JS, et al. Short communication: coronary heart disease risk by framingham risk score in hepatitis C and HIV/Hepatitis C-coinfected persons. AIDS Res Hum Retroviruses. 2015;31(7):718–22.
pubmed: 25858663
pmcid: 4505770
Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, et al. Significant reductions in alcohol use after Hepatitis C treatment: results from the French ANRS CO13-HEPAVIH cohort: significant reductions in alcohol use. Addiction. 2017;112:1669.
pubmed: 28430385
Fialho R, Pereira M, Rusted J, Whale R. Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis. Psychol Health Med. 2017;22(9):1089–104.
pubmed: 28100073
Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, et al. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int Off J Int Assoc Study Liver. 2015;35(1):65–70.
Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS Lond Engl. 2005;19(Suppl 3):S199-207.
Kariuki W, Manuel JI, Kariuki N, Tuchman E, O’Neal J, Lalanne GA. HIV and smoking: associated risks and prevention strategies. HIVAIDS (Auckland, NZ). 2015;8:17–36.
Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet Lond Engl. 2008;372(9635):293–9.
Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS Lond Engl. 2014;28(8):1181–91.
Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS Lond Engl. 2015;29(2):221–9.
Gartner C, Miller A, Bonevski B. Extending survival for people with hepatitis C using tobacco dependence treatment. Lancet. 2017;390(10107):2033.
pubmed: 29115237
Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, et al. Trends in cause-specific mortality in HIV–hepatitis C coinfection following hepatitis C treatment scale-up. AIDS. 2019;33(6):1013.
pubmed: 30946155
Caven M, Malaguti A, Robinson E, Fletcher E, Dillon JF. Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: a systematic review. Int J Drug Policy. 2019;72:169–76.
pubmed: 31109776
Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, et al. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clin Trials. 2015;16(3):100–10.
pubmed: 25972048
Loko M-A, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006–2010. BMC Infect Dis. 2010;10:303.
pubmed: 20969743
pmcid: 2988047
Prentiss D, Power R, Balmas G, Tzuang G, Israelski D. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr. 1999;2004(35):38–45.
Fischer B, Reimer J, Firestone M, Kalousek K, Rehm J, Heathcote J. Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions. Eur J Gastroenterol Hepatol. 2006;18(10):1039–42.
pubmed: 16957507
Santos ME, Protopopescu C, Sogni P, Yaya I, Piroth L, Bailly F, et al. HCV-related mortality among HIV/HCV co-infected patients: the importance of behaviors in the HCV cure era (ANRS CO13 HEPAVIH Cohort). AIDS Behav. 2020;24(4):1069–84.
pubmed: 31286317
Hindocha C, Freeman TP, Ferris JA, Lynskey MT, Winstock AR. No smoke without tobacco: a Global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front Psychiatry. 2016. https://doi.org/10.3389/fpsyt.2016.00104/full .
doi: 10.3389/fpsyt.2016.00104/full
pubmed: 27458388
pmcid: 4933835
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.
pubmed: 16729309
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.
Fuhrer R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l’échelle d’autoévaluation. Psychiatr Psychobiol. 1989;4(3):163–6.
Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, et al. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). HIV Med. 2018;19(3):227–37.
pubmed: 29214737
Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, et al. Development and validation of a self-completed HIV Symptom Index. J Clin Epidemiol. 2001;54(Suppl 1):S77.
pubmed: 11750213
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.
pubmed: 9738608
Allison PD. Discrete-time methods for the analysis of event histories. Sociol Methodol. 1982;13:61–98.
Butt AA, Yan P, Shuaib A, Abou-Samra A-B, Shaikh OS, Freiberg MS. Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events. Gastroenterology. 2019;156(4):987-996.e8.
pubmed: 30445009
Midgard H, Hajarizadeh B, Cunningham E, Conway B, Backmund M, Bruggmann P, et al. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: the ACTIVATE study. Int J Drug Policy. 2017;47:230.
pubmed: 28633998
Juanbeltz R, Martínez-Baz I, Miguel RS, Goñi-Esarte S, Cabasés JM, Castilla J. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS ONE. 2018;13(10):e0205277.
pubmed: 30300395
pmcid: 6177189
Castera L, Constant A, Bernard P-H, de Ledinghen V, Couzigou P. Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol. 2006;12(10):1545–50.
pubmed: 16570346
pmcid: 4124286
Revell AD, Warburton DM, Wesnes K. Smoking as a coping strategy. Addict Behav. 1985;10(3):209–24.
pubmed: 4083100
Fidler JA, West R. Self-perceived smoking motives and their correlates in a general population sample. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2009;11(10):1182–8.
Batchelder A, Peyser D, Nahvi S, Arnsten J, Litwin A. “Hepatitis C treatment turned me around:” psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend. 2015;153:66–71.
pubmed: 26096534
pmcid: 4759650
Torrens M, Soyemi T, Bowman D, Schatz E. Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment. BMC Infect Dis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517680/ (2020). Accessed 29 Oct 2020
Williams EB, Nelons D, Seaman A, Witkowska M, Ronan W, Wheelock H, et al. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. Int J Drug Policy. 2019;72:138–45.
Janda M, Mergenhagen KA. The effect of psychosocial factors on success rates of hepatitis C treatment. Psychosomatics. 2017;58(6):624–32.
pubmed: 28870488
de Dios MA, Stanton CA, Cano MÁ, Lloyd-Richardson E, Niaura R. The influence of social support on smoking cessation treatment adherence among HIV+ smokers. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2016;18(5):1126–33.
Soulakova JN, Tang C-Y, Leonardo SA, Taliaferro LA. Motivational benefits of social support and behavioural interventions for smoking cessation. J Smok Cessat. 2018;13(4):216–26.
pubmed: 30984294
Adeyemi OM, Jensen D, Attar B, Ghaoui R, Gallagher M, Wolen D, et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDs. 2004;18(4):239–45.
pubmed: 15142354
Dillon JF, Lazarus JV, Razavi HA. Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy. 2016;1(1):2.
pubmed: 30288305
pmcid: 5918492
Dever JB, Ducom JH, Ma A, Nguyen J, Liu L, Herrin A, et al. Engagement in care of high-risk hepatitis C patients with interferon-free direct-acting antiviral therapies. Dig Dis Sci. 2017;62(6):1472–9.
pubmed: 28378246
De Socio GV, Ricci E, Maggi P, Orofino G, Squillace N, Menzaghi B, et al. Is it feasible to impact on smoking habits in HIV-Infected patients? Mission impossible from the STOPSHIV Project cohort. J Acquir Immune Defic Syndr 1999. 2020;83:496.
Wray JM, Funderburk JS, Acker JD, Wray LO, Maisto SA. A meta-analysis of brief tobacco interventions for use in integrated primary care. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2018;20(12):1418–26.
Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824–35.
pubmed: 18777131
Bains M, Britton J, Marsh J, Jayes L, Murray RL. Patients’ and healthcare professionals’ views on a specialist smoking cessation service delivered in a United Kingdom hospital: a qualitative study. Tob Induc Dis. 2014;12(1):2.
pubmed: 24472521
pmcid: 3909354
Khara M, Okoli C, Nagarajan VD, Aziz F, Hanley C. Smoking cessation outcomes of referral to a specialist hospital outpatient clinic. Am J Addict. 2015;24(6):561–70.
pubmed: 26303966
Benard A, Bonnet F, Tessier J-F, Fossoux H, Dupon M, Mercie P, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDs. 2007;21(7):458–68.
pubmed: 17651027
Edwards SK, Dean J, Power J, Baker P, Gartner C. Understanding the prevalence of smoking among people living with HIV (PLHIV) in Australia and factors associated with smoking and quitting. AIDS Behav. 2020;24(4):1056–63.
pubmed: 31115754
Weinberger AH, Pacek LR, Wall MM, Gbedemah M, Lee J, Goodwin RD. Cigarette smoking quit ratios among adults in the USA with cannabis use and cannabis use disorders, 2002–2016. Tob Control. 2020;29(1):74–80.
pubmed: 30952691
Voci S, Zawertailo L, Baliunas D, Masood Z, Selby P. Is cannabis use associated with tobacco cessation outcome? An observational cohort study in primary care. Drug Alcohol Depend. 2020;206:107756.
pubmed: 31786396
Klein MB, Rollet-Kurhajec KC, Moodie EEM, Yaphe S, Tyndall M, Walmsley S, et al. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003–2013). AIDS Lond Engl. 2014;28(13):1957–65.
Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. Addict Abingdon Engl. 2012;107(7):1221–33.
McClure EA, Tomko RL, Salazar CA, Akbar SA, Squeglia LM, Herrmann E, et al. Tobacco and cannabis co-use: drug substitution, quit interest, and cessation preferences. Exp Clin Psychopharmacol. 2019;27(3):265–75.
pubmed: 30556733
Dierker L, Braymiller J, Rose J, Goodwin R, Selya A. Nicotine dependence predicts cannabis use disorder symptoms among adolescents and young adults. Drug Alcohol Depend. 2018;187:212–20.
pubmed: 29680677
pmcid: 5959804
Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002;13(5–6):451–63.
pubmed: 12394421
Rabin RA, George TP. A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am J Addict. 2015;24(2):105–16.
pubmed: 25662704
Ganzer F, Bröning S, Kraft S, Sack P-M, Thomasius R. Weighing the evidence: a systematic review on long-term neurocognitive effects of Cannabis use in abstinent adolescents and adults. Neuropsychol Rev. 2016;26(2):186–222.
pubmed: 27125202
Ashare RL, Schmidt HD. Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014;9(6):579–94.
pubmed: 24707983
pmcid: 4287224
McCabe SE, West BT. The three-year course of multiple substance use disorders in the United States: a National Longitudinal Study. J Clin Psychiatry. 2017;78(5):e537–44.
pubmed: 28406266
pmcid: 5453813
McKelvey K, Thrul J, Ramo D. Impact of quitting smoking and smoking cessation treatment on substance use outcomes: an updated and narrative review. Addict Behav. 2017;65:161–70.
pubmed: 27816663
Subbaraman MS. Substitution and complementarity of alcohol and Cannabis: a review of the literature. Subst Use Misuse. 2016;51(11):1399–414.
pubmed: 27249324
pmcid: 4993200
Allsop DJ, Dunlop AJ, Saddler C, Rivas GR, McGregor IS, Copeland J. Changes in cigarette and alcohol use during cannabis abstinence. Drug Alcohol Depend. 2014;138:54–60.
pubmed: 24613633
Ducci F, Goldman D. The genetic basis of addictive disorders. Psychiatr Clin North Am. 2012;35(2):495–519.
pubmed: 22640768
pmcid: 3506170
Loflin M, Earleywine M. No smoke, no fire: What the initial literature suggests regarding vapourized cannabis and respiratory risk. Can J Respir Ther CJRT Rev Can Thérapie Respir RCTR. 2015;51(1):7–9.
Lanz C, Mattsson J, Soydaner U, Brenneisen R. Medicinal Cannabis: In Vitro Validation of vaporizers for the smoke-free inhalation of Cannabis. PLoS ONE 11(1). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718604/ (2016). Accessed 8 Sept 2020
Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial. PLoS ONE. 2018;13(1):e0190768.
pubmed: 29385147
pmcid: 5791962
Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland J, McGregor I, et al. Nabiximols for the treatment of Cannabis dependence: a randomized clinical trial. JAMA Intern Med. 2019;179:1242.
pubmed: 31305874
pmcid: 6632121
Lintzeris N, Mills L, Dunlop A, Copeland J, Mcgregor I, Bruno R, et al. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial. Drug Alcohol Depend. 2020;215:108220.
pubmed: 32768992
Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8(3):313–9.
pubmed: 21653534
pmcid: 3132791
Encrenaz G, Bénard A, Rondeau V, Bonnet F, Lazaro E, Neau D, et al. Determinants of smoking cessation attempts among HIV-infected patients results from a hospital-based prospective cohort. Curr HIV Res. 2010;8(3):212–7.
pubmed: 20158455
Weinberger AH, Seng EK, Esan H, Shuter J. Perceived risks and benefits of quitting smoking in a sample of adults living with HIV/AIDS. AIDS Care. 2018;30(5):564–8.
pubmed: 28975812
Peretti-Watel P, Garelik D, Baron G, Spire B, Ravaud P, Duval X, et al. Smoking motivations and quitting motivations among HIV-infected smokers. Antivir Ther. 2009;14(6):781–7.
pubmed: 19812440
Chaiton M, Diemert L, Cohen JE, Bondy SJ, Selby P, Philipneri A, et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open 6(6). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908897/ (2016). Accessed 14 Jan 2020
Shahab L, Gilchrist G, Hagger-Johnson G, Shankar A, West E, West R. Reciprocal associations between smoking cessation and depression in older smokers: findings from the English Longitudinal Study of Ageing. Br J Psychiatry J Ment Sci. 2015;207(3):243–9.
Harris GE, Dupuis L, Mugford GJ, Johnston L, Haase D, Page G, et al. Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol. 2014;25(1):e1-7.
pubmed: 24634690
pmcid: 3950986
Hasin D, Walsh C. Cannabis use, Cannabis use disorder, and comorbid psychiatric illness: a narrative review. J Clin Med. 2020;10(1):15.
pmcid: 7793504
Pacek LR, Towe SL, Hobkirk AL, Nash D, Goodwin RD. Frequency Of Cannabis use and medical cannabis use among persons living with HIV In The United States: findings from a nationally representative sample. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 2018;30(2):169–81.
Regan S, Meigs JB, Grinspoon SK, Triant VA. Determinants of Smoking and Quitting in HIV-Infected Individuals. PLoS ONE 21 11(4). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839777/ (2016). Accessed 7 Nov 2019